Treatment of type 1 diabetes mellitus (T1DM) for individuals over the age of 30 years is often delayed. A recent large-scale population analysis used a genetic risk score to define T1DM in the first six decades of life, providing specific insights applicable to those >30 years of age.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Thomas, N. J. et al. Frequency and phenotype of type 1 diabetes in the first six decades of life: a cross-sectional, genetically stratified survival analysis from UK Biobank. Lancet Diabetes Endocrinol. https://doi.org/10.1016/S2213-8587(17)30362-5 (2017).
Patel, K. A. Type 1 diabetes genetic risk score: a novel tool to discriminate monogenic and type 1 diabetes. Diabetes 65, 2094–2099 (2016).
Bingley, P. J. Clinical applications of diabetes antibody testing. J. Clin. Endocrinol. Metab. 95, 25–33 (2010).
DuBose, S. N. et al. Obesity in youth with type 1 diabetes in Germany, Austria, and the United States. J. Pediatr. 167, 627–632 (2015).
Douek, I. F. et al. Diabetes in the parents of children with type I diabetes. Diabetologia 45, 495–501 (2002).
Järvelä, I. Y. et al. Gestational diabetes identifies women at risk for permanent type 1 and type 2 diabetes in fertile age: predictive role of autoantibodies. Diabetes Care 29, 607–612 (2006).
Lamberts, L. E. et al. Immune-mediated diseases in primary sclerosing cholangitis. Dig. Liver Dis. 43, 802–806 (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
E.H.M. is funded by the NIH (including 1P30DK116074), JDRF Career Development Award and the Helmsley Charitable Trust. He has no conflicts regarding this topic, but is an adviser and equity holder in GigaGen and Triursus Therapeutics. He also is on an advisory board for Incyte. D.M.M. is funded by the NIH (including 1P30DK116074), JDRF, NSF and the Helmsley Charitable Trust. He has no conflicts regarding this topic, but is on an advisory board for Insulet, has consulted for Abbott Diabetes Care and the Helmsley Charitable Trust, and his institution has received research support or materials from Medtronic, Dexcom, Insulet, Bigfoot Biomedical, Type Zero and Roche.
Rights and permissions
About this article
Cite this article
Meyer, E., Maahs, D. Quantifying genetic susceptibility in T1DM — implications for diagnosis after age 30. Nat Rev Endocrinol 14, 134–135 (2018). https://doi.org/10.1038/nrendo.2018.7
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2018.7